CTXR
Citius Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.55
−2.61%Oct 26, 2026, 17:00 UTC
Citius Pharmaceuticals, Inc. reported preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026, with shipments of LYMPHIR units to U.S. wholesalers up 120%.
Source:Aug 14, 2026, 20:30 UTC
Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, with $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and $17 million in cash and cash equivalents as of June 30, 2026.
Source:Aug 12, 2026, 12:00 UTC
Citius Oncology appointed Jonathan Peri as an independent director to its board.
Source: